Telephone: +351-22-5570700; Fax: +351-22-5570799
Cancer Stem Cells
Article first published online: 9 APR 2012
Copyright © 2012 AlphaMed Press
Volume 30, Issue 5, pages 854–864, May 2012
How to Cite
Vieira, A. F., Ricardo, S., Ablett, M. P., Dionísio, M. R., Mendes, N., Albergaria, A., Farnie, G., Gerhard, R., Cameselle-Teijeiro, J. F., Seruca, R., Schmitt, F., Clarke, R. B. and Paredes, J. (2012), P-Cadherin Is Coexpressed with CD44 and CD49f and Mediates Stem Cell Properties in Basal-like Breast Cancer. STEM CELLS, 30: 854–864. doi: 10.1002/stem.1075
Author contributions: A.F.V.: conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing; S.R.: collection and/or assembly of data and data analysis and interpretation; M.P.A., M.R.D., and N.M.: collection and/or assembly of data; A.A., G.F., R.G., R.S., and F.S.: data analysis and interpretation; J.F.C.-T.: provision of study material or patients; R.B.C.: conception and design, provision of study material or patients, and data analysis and interpretation; J.P.: conception and design, data analysis and interpretation, manuscript writing, and final approval of manuscript.
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS March 2, 2012.
- Issue published online: 9 APR 2012
- Article first published online: 9 APR 2012
- Accepted manuscript online: 2 MAR 2012 04:21PM EST
- Manuscript Accepted: 7 FEB 2012
- Manuscript Received: 16 SEP 2011
- Fundação Gulbenkian, Portugal. Grant Number: Project 96633-2010
- Programa Ciência 2007
- POPH—QREN—Tipology 4.2
- Fundação Gulbenkian
- Fundação Champalimaud, Portuguese Ministry of Science, Technology and Higher Education and FCT, Portugal
Additional Supporting Information may be found in the online version of this article.
|STEM_1075_sm_SuppFig1.tif||1172K||Supplementary Figure 1. Flow cytometric analysis of P-cadherin expression in the subpopulations defined by CD49f/CD24 expression in a panel of luminal and basal breast cell lines. In all cell lines indicated (except BT-20), the quadrant CD49f+/CD24+ showed a higher P-cadherin expression. * indicates ≤ 1,5% of the total population.|
|STEM_1075_sm_SuppFig2.tif||749K||Supplementary Figure 2. Overall survival and univariate analysis (log-rank test) of patients with breast carcinomas, according to the expression of CD44 (A), CD24 (B), CD49f (C) and ALDH1 (D). Expression of CD44, CD49f or ALDH1 alone do not show any prognostic value. However, although expression of CD24 alone has not reached significance, there is a tendency for CD24- cases to have a worse prognosis than CD24+ cases (p=0.073).|
|STEM_1075_sm_SuppFig3.pdf||307K||Supplementary Figure 3. Immunohistochemical representation of CD44, P-cadherin and CD49f showing positivity for the three stem cell markers in the same breast carcinoma case.|
|STEM_1075_sm_SuppFig4.tif||898K||Supplementary Figure 4. Hoechst-33342 stain of the cell cycle profile in the basal cell lines MCF10A, BT-20 and BT-549 revealed that inhibition of P-cadherin did not affect the proliferative phase of the cell cycle (G2M).|
|STEM_1075_sm_SuppTab1.tif||334K||Supplementary Table 1. Patient and tumor parameters of the series of 466 primary invasive breast carcinomas.|
|STEM_1075_sm_SuppTab2.tif||352K||Supplementary Table 2. Association between the expression of P-cadherin, CD44, CD24, CD49f and ALDH1 and the major breast cancer molecular subtypes. There is a statistically significant association between positive expression for P-cadherin, CD44, CD49f and ALDH1 and the basal-like molecular subtype.|
|STEM_1075_sm_SuppTab3.tif||807K||Suplementary Table 3. Multivariate Cox proportional hazard analysis (for overall patient survival), with models including the classical prognostic factors in breast cancer (tumor size, nodal status and histological grade), for P-cadherin, CD44, CD24, CD49f and ALDH1 expression. P-cadherin expression appears as an independent factor of worse prognosis, whereas expression of CD24 is an independent factor of good breast cancer patient prognosis.|
Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.